Lotus Eye Hospital and Institute Limited (532998) Fair Value & Analysis
Other · IN · Market cap ₹563M
Fair value as of: Jul 4, 2026
From 15 valuation models · updated 4 days ago
Share price +18.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹69.63 – ₹141.10 · fair‑value band ₹21.72 – ₹36.21 · the ₹129.65 price screens above the ₹28.97 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lotus Eye Hospital and Institute Limited (532998) currently trades at ₹129.65, while our model-based Fair Value estimate is ₹28.97 — implying the stock looks roughly 77.7% overvalued today. We read business quality at 58/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
The stock trades on a trailing P/E of 26.8. Fundamentals as of Jul 4, 2026
Our scenario range runs from ₹21.72 (bear case) to ₹36.21 (bull case); at ₹129.65, the current price sits above that range. The share trades about 15% below its 52-week high and 82% above its 52-week low. For context, the median of 10 Other peers we cover trades at -16% fair-value upside — at -78%, 532998 screens richer than that median.
About the company
Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care and related services in India. It provides services in the areas of refractive surgery, glaucoma, retina and uvea, cornea, paediatric and squint, orbit and oculoplasty, and neuro ophthalmology. The company also offers cataracts and intraocular lenses, as well as operates an eye bank. In addition, it provides ophthalmic fellowship training courses in cornea, glaucoma, retina, and anterior segments, as well as DNB teaching and training services. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was incorporated in 1997 and is based in Coimbatore, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lotus Eye Hospital and Institute Limited reported revenue of ₹496M in FY2025 versus ₹324M in FY2021, a compound +11.2%/yr. Reported net income was ₹7.4M in FY2025, compounding −17.1%/yr from FY2021.
Is 532998 fairly valued? → Check now
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
| 540777 540777 | ₹567.55 | ₹142.69 | -75% |
| Lupin Limited 500257 | ₹2,476 | ₹2,372 | -4% |
| 540719 540719 | ₹1,788 | ₹850.02 | -52% |
| 524804 524804 | ₹1,620 | ₹1,368 | -16% |
Explore undervalued stocks
Frequently asked questions
Is Lotus Eye Hospital and Institute Limited (532998) undervalued?
What is the fair value of 532998?
What is the quality score of 532998?
What is the net profit margin of 532998?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.